ArticleJournal of translational medicine2018
MiR-362-5p as a novel prognostic predictor of cytogenetically normal acute myeloid leukemia.
Article in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Overexpression of Sterol Regulatory Element-binding Transcription Factor 2 is associated with an adverse prognosis in cytogenetically normal acute myeloid leukemia.Discover oncology · 2025Article
- Functions, mechanisms, and therapeutic implications of noncoding RNA in acute myeloid leukemia.Fundamental research · 2025Review
- Article
- A novel 5-gene prognostic signature to improve risk stratification of cytogenetically normal acute myeloid leukemia.Journal of cancer research and clinical oncology · 2023Article
- The Promising Role of Non-Coding RNAs as Biomarkers and Therapeutic Targets for Leukemia.Genes · 2023Review
- Research progress on molecular biomarkers of acute myeloid leukemia.Frontiers in oncology · 2023Review
- Identification of circRNA-miRNA-Immune-Related mRNA Regulatory Network in Gastric Cancer.Frontiers in oncology · 2022Article
- MicroRNA-362-5p promotes the proliferation and inhibits apoptosis of trophoblast cells via targeting glutathione-disulfide reductase.Bioengineered · 2021Article
- miR-4792 Inhibits Acute Myeloid Leukemia Cell Proliferation and Invasion and Promotes Cell Apoptosis by Targeting Kindlin-3.Oncology research · 2020Article
- Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia.Cancer biomarkers : section A of Disease markers · 2020Article
- EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia.Journal of cellular and molecular medicine · 2020Article
- Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia.Bioengineered · 2019Article
- Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia.Journal of hematology & oncology · 2019Review
- Selection of three miRNA signatures with prognostic value in non-M3 acute myeloid leukemia.BMC cancer · 2019Article
- MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia.Frontiers in oncology · 2019Article
- Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.Disease markers · 2019Article
- microRNA-628 inhibits the proliferation of acute myeloid leukemia cells by directly targeting IGF-1R.OncoTargets and therapy · 2019Article
- miR‑1271‑5p inhibits cell proliferation and induces apoptosis in acute myeloid leukemia by targeting ZIC2.Molecular medicine reports · 2019Article
- MicroRNAs in Autoimmunity and Hematological Malignancies.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMicroRNAs are of special interest in cancer research and hold significant promise as diagnostic and prognostic biomarkers for malignant disease. MiR-362-5p have been found to exert both oncogenic and tumor suppressive effects depending highly on the cellular context. The aim of this study was to determine whether the expression of miR-362-5p can be served as a prognostic factor for patients with cytogentically normal acute myeloid leukemia (CN-AML).
methodsWe enrolled 224 patients with CN-AML and measured the expression of miR-362-5p by quantitative real time PCR analysis. We classified patients into high and low expression based on the median value. The Cox regression analyses were carried out to assess the prognostic significance of miR-362-5p expression in the context of the well-established predictors. Additionally, microRNA expression profiling were conducted to identify the biological insights between high and low group.
resultsHigh expressers had older age. High expressers obtained shorter overall survival in the univariate analysis. The independent prognostic value of miR-362-5p remained in the context of the well-established clinical and cytogenetic predictors. Moreover, the prognostic value of miR-362-5p was also validated in an independent cohort of CN-AML. Notably, numerous oncomiRs were also high expressed in high miR-362-5p group.
conclusionHigh miR-362-5p expression was associated with poorer overall survival implicating the oncogenic function in AML development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.